143 related articles for article (PubMed ID: 29620680)
21. Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study.
Tse CY; Chow AM; Chan SC
Hong Kong Med J; 2000 Sep; 6(3):260-4. PubMed ID: 11025843
[TBL] [Abstract][Full Text] [Related]
22. The protective effect of fenofibrate, triptorelin, and their combination against premature ovarian failure in rats.
Abdelzaher WY; Abdel-Hafez SMN; Rofaeil RR; Ali AHSA; Hegazy A; Bahaa HA
Naunyn Schmiedebergs Arch Pharmacol; 2021 Jan; 394(1):137-149. PubMed ID: 32924068
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide.
Karimi-Zarchi M; Forat-Yazdi M; Vafaeenasab MR; Nakhaie-Moghadam M; Miratashi-Yazdi A; Teimoori S; Dehghani-Tafti A
Eur J Gynaecol Oncol; 2014; 35(1):59-61. PubMed ID: 24654464
[TBL] [Abstract][Full Text] [Related]
24. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
Munhoz RR; Pereira AA; Sasse AD; Hoff PM; Traina TA; Hudis CA; Marques RJ
JAMA Oncol; 2016 Jan; 2(1):65-73. PubMed ID: 26426573
[TBL] [Abstract][Full Text] [Related]
25. Is Menstruation or the Serum Hormone Level a Useful Predictor for Live Birth after Gonadotropin-Releasing Hormone Agonist during Chemotherapy in Young Breast Cancer Patients.
Lee DY; Choi D
Gynecol Obstet Invest; 2017; 82(6):601-606. PubMed ID: 28006769
[TBL] [Abstract][Full Text] [Related]
26. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group.
Emons G; Ortmann O; Teichert HM; Fassl H; Löhrs U; Kullander S; Kauppila A; Ayalon D; Schally A; Oberheuser F
Cancer; 1996 Oct; 78(7):1452-60. PubMed ID: 8839551
[TBL] [Abstract][Full Text] [Related]
27. Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists.
Blumenfeld Z; Evron A
Expert Opin Pharmacother; 2015 May; 16(7):1009-20. PubMed ID: 25826240
[TBL] [Abstract][Full Text] [Related]
28. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
Reyes FI; Winter JS; Faiman C
Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
[TBL] [Abstract][Full Text] [Related]
29. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
[TBL] [Abstract][Full Text] [Related]
30. A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy.
Whitehead J; Toledo MG; Stern CJ
Aust N Z J Obstet Gynaecol; 2011 Oct; 51(5):452-4. PubMed ID: 21810087
[TBL] [Abstract][Full Text] [Related]
31. Preservation of gonadal function in women undergoing chemotherapy: a review of the potential role for gonadotropin-releasing hormone agonists.
Hickman LC; Valentine LN; Falcone T
Am J Obstet Gynecol; 2016 Oct; 215(4):415-22. PubMed ID: 27422055
[TBL] [Abstract][Full Text] [Related]
32. Endocrine prevention of chemotherapy-induced ovarian failure.
Blumenfeld Z; Evron A
Curr Opin Obstet Gynecol; 2016 Aug; 28(4):223-9. PubMed ID: 27253235
[TBL] [Abstract][Full Text] [Related]
33. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
Blumenfeld Z; Zur H; Dann EJ
Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
[TBL] [Abstract][Full Text] [Related]
34. Ovarian hyperstimulation syndrome following the sole administration of injectable gonadotropin-releasing hormone agonist (triptorelin) for the pituitary down-regulation and in vitro fertilization treatment: report of two cases.
Qublan HS; Beni-Merei Z; Megdadi M; Al-Quraan G
Arch Gynecol Obstet; 2009 Feb; 279(2):221-3. PubMed ID: 18461341
[TBL] [Abstract][Full Text] [Related]
35. Transplantation of adipose-derived stem cells combined with collagen scaffolds restores ovarian function in a rat model of premature ovarian insufficiency.
Su J; Ding L; Cheng J; Yang J; Li X; Yan G; Sun H; Dai J; Hu Y
Hum Reprod; 2016 May; 31(5):1075-86. PubMed ID: 26965432
[TBL] [Abstract][Full Text] [Related]
36. Establishment of a Mouse Model of Premature Ovarian Failure Using Consecutive Superovulation.
Nie X; Dai Y; Zheng Y; Bao D; Chen Q; Yin Y; Fu H; Hou D
Cell Physiol Biochem; 2018; 51(5):2341-2358. PubMed ID: 30537739
[TBL] [Abstract][Full Text] [Related]
37. [Premature ovarian failure in patients affected by oncohematological disease].
Marchesoni D; Driul L; Fruscalzo A; Santuz M; Calcagno A; Ianni A; Geromin A; Fanin R
Minerva Ginecol; 2005 Oct; 57(5):545-50. PubMed ID: 16205599
[TBL] [Abstract][Full Text] [Related]
38. Gonadotropin suppression for the treatment of karyotypically normal spontaneous premature ovarian failure: a controlled trial.
Nelson LM; Kimzey LM; White BJ; Merriam GR
Fertil Steril; 1992 Jan; 57(1):50-5. PubMed ID: 1730330
[TBL] [Abstract][Full Text] [Related]
39. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients.
Conte B; Del Mastro L
Minerva Ginecol; 2017 Aug; 69(4):350-356. PubMed ID: 28398024
[TBL] [Abstract][Full Text] [Related]
40. Assessment of Estradiol Response after Depot Triptorelin Administration in Girls with Central Precocious Puberty.
Freire AV; Gryngarten MG; Ballerini MG; Arcari AJ; Escobar ME; Bergadá I; Ropelato MG
Horm Res Paediatr; 2016; 85(1):58-64. PubMed ID: 26675317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
